Modeling the Probability of Sustained Virological Response to Therapy with Pegylated Interferon plus Ribavirin in Patients Coinfected with Hepatitis C Virus and HIV | Zendy

J. Medraño | Zendy; Karin Neukam | Zendy; Norma Rallón | Zendy; Antonio Rivero | Zendy; Salvador Resino | Zendy; Susanggie | Zendy; Antonio Carúz | Zendy; Aida Calviño | Zendy; Juan Macı́as | Zendy; José M. Benito | Zendy; Carlos SánchezPiedra | Zendy; Eugenia Vispo | Zendy; Pablo Barreiro | Zendy; John G. McHutchison | Zendy; Juan A. Pineda | Zendy; Vincent Soriano | Zendy

Open Access

Modeling the Probability of Sustained Virological Response to Therapy with Pegylated Interferon plus Ribavirin in Patients Coinfected with Hepatitis C Virus and HIV

Author(s) -

J. Medraño,

Karin Neukam,

Norma Rallón,

Antonio Rivero,

Salvador Resino,

Susanggie,

Antonio Carúz,

Aida Calviño,

Juan Macı́as,

José M. Benito,

Carlos SánchezPiedra,

Eugenia Vispo,

Pablo Barreiro,

John G. McHutchison,

Juan A. Pineda,

Vincent Soriano

Publication year - 2010

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/656811

Subject(s) - ribavirin , medicine , pegylated interferon , hepatitis c virus , virology , hepatitis c , human immunodeficiency virus (hiv) , antiretroviral therapy , hepacivirus , interferon , immunology , viral load , virus

A single-nucleotide polymorphism (SNP) near the IL28B gene (rs12979860) strongly predicts sustained virological response to pegylated interferon plus ribavirin (pegIFN-RBV) treatment for chronic hepatitis C virus (HCV) infection. Given that therapy is poorly tolerated and rates of response are lower in patients coinfected with HCV and human immunodeficiency virus (HIV), the recognition of predictors of response is a high priority in this population.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research